Arbutus Biopharma announced that the FDA has lifted the clinical hold on its Investigational New Drug application for AB-101, an oral PD-L1 inhibitor, allowing the company to further evaluate its potential for treating chronic HBV infection.
Arbutus Biopharma announced that the FDA has lifted the clinical hold on its Investigational New Drug application for AB-101, an oral PD-L1 inhibitor, allowing the company to further evaluate its potential for treating chronic HBV infection.